You are viewing the site in preview mode
Skip to main content
|
Outcomes
|
First author
|
Year
|
Types of milk
|
No. of studies in MA
|
Type of studies in MA
|
No. of cases/total
|
Effects mode
|
Metric of MA
|
Effect size
|
95% CI
|
I2%
|
Publication bias
|
|---|
|
Significant associations
|
|
Most beneficial
|
|
Colon cancer
|
Barrubes
|
2019
|
Low-fat milk
|
2
|
Cohort
|
3339/15,441
|
Fixed
|
RR
|
0.73
|
0.61–0.87
|
0
|
NA
|
|
Distal colon cancer
|
Barrubes
|
2019
|
Milk
|
3
|
Cohort
|
40,651/15,657
|
Fixed
|
RR
|
0.75
|
0.63–0.90
|
25
|
NA
|
|
CRC
|
Barrubes
|
2019
|
Low-fat milk
|
2
|
Cohort
|
3507/484,338
|
Fixed
|
RR
|
0.76
|
0.66–0.88
|
42
|
NA
|
|
Colon cancer
|
Barrubes
|
2019
|
Milk
|
8
|
Cohort
|
3339/15,441
|
Random
|
RR
|
0.79
|
0.72–0.87
|
0
|
NA
|
|
Proximal colon cancer
|
Barrubes
|
2019
|
Milk
|
3
|
Cohort
|
40,651/15,657
|
Fixed
|
RR
|
0.81
|
0.68–0.96
|
0
|
NA
|
|
CRC
|
Barrubes
|
2019
|
Milk
|
9
|
Cohort
|
9118/1,003,303
|
Random
|
RR
|
0.82
|
0.76–0.88
|
2
|
NA
|
|
Rectal cancer
|
Barrubes
|
2019
|
Milk
|
5
|
Cohort
|
NA
|
Random
|
RR
|
0.84
|
0.73–0.97
|
0
|
NA
|
|
Colon cancer
|
Barrubes
|
2019
|
Milk
|
3
|
Cohort
|
3339/15,441
|
Fixed
|
RRa
|
0.88
|
0.84–0.93
|
0
|
NA
|
|
Bladder Cancer
|
Bermejo
|
2019
|
Milk
|
14
|
Cohort/case control
|
NA/438,319
|
Random
|
RR
|
0.89
|
0.81–0.98
|
66.4
|
0.269
|
|
CRC
|
Barrubes
|
2019
|
Milk
|
9
|
Cohort
|
9118/1,003,303
|
Random
|
RRb
|
0.90
|
0.86–0.93
|
0
|
NA
|
|
Rectal cancer
|
Barrubes
|
2019
|
Milk
|
3
|
Cohort
|
NA
|
Fixed
|
RRc
|
0.91
|
0.84–0.97
|
25
|
NA
|
|
Prostate cancer
|
Aune
|
2015
|
Milk
|
8
|
Cohort
|
19,664/448,719
|
Random
|
RR
|
0.92
|
0.85–0.99
|
0
|
No
|
|
Breast cancer
|
Wu
|
2016
|
Skim milk
|
8
|
Cohort
|
16,664/586,726
|
Random
|
RR
|
0.93
|
0.85–1.00
|
40.1
|
0.616
|
|
Breast cancer
|
Wu
|
2016
|
Skim milk
|
5
|
Cohort
|
NA
|
Random
|
RR
|
0.96
|
0.92–1.00
|
11.9
|
0.498
|
|
Most harmful
|
|
DLBCL
|
Wang
|
2016
|
Milk
|
3
|
Case–control
|
352/NA
|
Random
|
RR
|
1.49
|
1.08–2.06
|
8.9
|
NA
|
|
Gastric cancr
|
Wang
|
2018
|
Milk
|
21
|
Cohort/case control
|
NA
|
Random
|
RR
|
1.44
|
1.15–1.81
|
82.7
|
NA
|
|
NHL
|
Wang
|
2016
|
Milk
|
14
|
Cohort/case control
|
7109/NA
|
Random
|
RR
|
1.41
|
1.08–1.84
|
88.6
|
no
|
|
Ovarian cancer
|
Liu
|
2015
|
Milk
|
11
|
Cohort
|
NA
|
Random
|
OR
|
1.23
|
1.03–1.46
|
> 50
|
0.957
|
|
Bladder Cancer
|
Bermejo
|
2019
|
Milk
|
3
|
Cohort/case control
|
NA/3933
|
Random
|
RR
|
1.21
|
1.04–1.38
|
86.1
|
NA
|
|
Prostate cancer
|
Aune
|
2015
|
Low-fat milk
|
6
|
Cohort
|
19,430/432,943
|
Random
|
RRd
|
1.14
|
1.05–1.25
|
51
|
NA
|
|
NHL
|
Wang
|
2016
|
Milk
|
9
|
Cohort/case control
|
3739/NA
|
Random
|
RRe
|
1.13
|
1.00–1.28
|
NA
|
NA
|
|
NHL
|
Wang
|
2016
|
Milk
|
9
|
Cohort/case control
|
3739/NA
|
Random
|
RRf
|
1.12
|
1.00–1.26
|
NA
|
NA
|
|
Prostate cancer
|
Aune
|
2015
|
Milk
|
14
|
Cohort
|
11,392/566,146
|
Random
|
RR
|
1.11
|
1.03–1.21
|
21
|
no
|
|
Prostate cancer
|
Aune
|
2015
|
Low-fat milk
|
5
|
Cohort
|
NA/374,664
|
Random
|
RRg
|
1.06
|
1.01–1.11
|
67
|
NA
|
|
Prostate cancer
|
Aune
|
2015
|
Milk
|
13
|
Cohort
|
NA/559,383
|
Random
|
RRg
|
1.03
|
1.00–1.06
|
9
|
NA
|
|
Non-significant associations
|
|
Distal colon cancer
|
Barrubes
|
2019
|
Milk
|
2
|
Cohort
|
40,651/15,657
|
Fixed
|
RR
|
0.78
|
0.60–1.01
|
0
|
NA
|
|
Breast cancer
|
Chen
|
2019
|
Low-fat milk
|
3
|
Case–control
|
NA
|
Random
|
OR
|
0.85
|
0.70–1.04
|
< 50
|
0.583
|
|
Colon cancer
|
Barrubes
|
2019
|
Milk
|
2
|
Cohort
|
3339/15,441
|
Fixed
|
RR
|
0.87
|
0.72–1.05
|
0
|
NA
|
|
Pancreatic cancer
|
Genkinger
|
2014
|
Low-fat milk
|
14
|
Cohort
|
307/NA
|
Random
|
HR
|
0.87
|
0.75–1.01
|
5
|
NA
|
|
Breast cancer
|
Wu
|
2016
|
Milk
|
18
|
Cohort
|
19,747/775,778
|
Random
|
RR
|
0.92
|
0.84–1.02
|
53.5
|
0.292
|
|
Pancreatic cancer
|
Genkinger
|
2014
|
Milk
|
14
|
Cohort
|
373/NA
|
Random
|
HR
|
0.92
|
0.77–1.10
|
0
|
NA
|
|
Ovarian cancer
|
Liu
|
2015
|
Low-fat/skim milk
|
13
|
Cohort
|
NA
|
Random
|
OR
|
0.93
|
0.79–1.09
|
< 50
|
0.370
|
|
ESCC
|
Li
|
2016
|
Milk
|
11
|
Case–control
|
2311/NA
|
Random
|
RR
|
0.93
|
0.74–1.16
|
52.9
|
0.960
|
|
Rectal cancer
|
Barrubes
|
2019
|
Milk
|
2
|
Cohort
|
NA
|
Fixed
|
RR
|
0.94
|
0.76–1.16
|
0
|
NA
|
|
Breast cancer
|
Chen
|
2019
|
Milk
|
8
|
Case–control
|
NA
|
Random
|
OR
|
0.95
|
0.80–1.13
|
< 50
|
0.272
|
|
CRC
|
Barrubes
|
2019
|
Milk
|
3
|
Cohort
|
5198/545,046
|
Fixed
|
RR
|
0.97
|
0.86–1.09
|
40
|
NA
|
|
Breast cancer
|
Wu
|
2016
|
Milk
|
11
|
Cohort
|
NA
|
Random
|
RRg
|
0.97
|
0.93–1.01
|
36.4
|
0.355
|
|
ESCC
|
Li
|
2016
|
Milk
|
6
|
Case–control
|
NA
|
Random
|
RRb
|
0.97
|
0.70–1.35
|
58.9
|
NA
|
|
Lung cancer
|
Yang
|
2016
|
Low-fat milk
|
3
|
Cohort/case control
|
NA
|
Random
|
RR
|
0.98
|
0.69–1.41
|
0
|
0.120
|
|
Prostate cancer
|
Aune
|
2015
|
Milk
|
6
|
Cohort
|
NA/388,664
|
Random
|
RRg
|
0.98
|
0.95–1.01
|
0
|
NA
|
|
NHL
|
Sergentanis
|
2019
|
Milk
|
4
|
Cohort
|
1517/NA
|
Random
|
RR
|
0.99
|
0.85–1.15
|
0
|
0.461
|
|
Breast cancer
|
Wu
|
2016
|
Milk
|
9
|
Cohort
|
13,781/554,775
|
Random
|
RR
|
0.99
|
0.87–1.12
|
37.4
|
0.723
|
|
Endometrial cancer
|
Li
|
2017
|
Milk
|
6
|
Cohort/case control
|
3538/331,168
|
Random
|
OR
|
0.99
|
0.89–1.10
|
0
|
NA
|
|
FL
|
Wang
|
2016
|
Milk
|
3
|
Case–control
|
390/NA
|
Random
|
RR
|
0.99
|
0.47–2.07
|
89.8
|
NA
|
|
Pancreatic cancer
|
Genkinger
|
2014
|
Milk
|
14
|
Cohort
|
145/NA
|
Random
|
HR
|
1.01
|
0.83–1.22
|
0
|
NA
|
|
Breast cancer
|
Wu
|
2016
|
Milk
|
5
|
Cohort
|
NA
|
Random
|
RRg
|
1.02
|
0.92–1.13
|
32.8
|
0.660
|
|
NHL
|
Wang
|
2016
|
Milk
|
9
|
Cohort/case control
|
3739/NA
|
Random
|
RRh
|
1.04
|
0.97–1.12
|
NA
|
NA
|
|
SLL/CLL
|
Wang
|
2016
|
Milk
|
3
|
Case–control
|
477/NA
|
Random
|
RR
|
1.04
|
0.69–1.55
|
44.1
|
NA
|
|
NHL
|
Wang
|
2016
|
Milk
|
9
|
Cohort/case control
|
3739/NA
|
Random
|
RRi
|
1.07
|
0.96–1.19
|
NA
|
NA
|
|
Lung cancer
|
Yang
|
2016
|
Milk
|
22
|
Cohort/case control
|
NA
|
Random
|
RR
|
1.08
|
0.80–1.46
|
90.5
|
0.300
|
|
NHL
|
Wang
|
2016
|
Milk
|
9
|
Cohort/case control
|
3739/NA
|
Random
|
RRj
|
1.11
|
0.99–1.24
|
NA
|
NA
|
|
HCC
|
Yang
|
2017
|
Milk
|
7
|
Cohort/case control
|
NA
|
Random
|
RR
|
1.13
|
0.67–1.88
|
78
|
> 0.1
|
|
Proximal colon cancer
|
Barrubes
|
2019
|
Milk
|
2
|
Cohort
|
40,651/15,657
|
Fixed
|
RR
|
1.20
|
0.96–1.49
|
83
|
NA
|
- MA meta-analysis, CI confidence interval, RR risk ratio, HR hazard ratio, OR odds ratio, NHL non-Hodgkin’s lymphoma, HCC hepatocellular carcinoma, CRC colorectal cancer, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, SLL/CLL small lymphocytic lymphoma/chronic lymphocytic leukemia, ESCC esophageal squamous cell carcinoma, NA not available
- a488 g/day; b244 g/day; c732 g/day; dhighest verse lowest; e200 g/day; f440 g/day; g490 g/day; h120 g/day; i210 g/day; j370 g/day